# Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)

Amneal Pharmaceuticals' stock hits a 52-week and all-time high, driven by positive social sentiment and FDA approvals. However, margin pressure and patent lawsuits present ongoing challenges.

### About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc. Class A Common Stock is a publicly traded pharmaceutical company.  
Amneal Pharmaceuticals, Inc. Class A Common Stock uses the ticker $AMRX for trading. Listed in the [Stocks](/list/stocks) category.

### Insights
- Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) social dominance is up 257.14% from the previous week.
- Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) engagements is up 216.89% from the previous week.
- Amneal Pharmaceuticals, Inc. Class A Common Stock Price hit a 52-Week high of $15 for the hour
- Amneal Pharmaceuticals, Inc. Class A Common Stock Price hit an all time of $15 for the hour

### Price: $14.80
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:$amrx/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/$amrx/time-series/close.tsv)  
The stock price hit a 52-week and all-time high, likely driven by positive social sentiment, FDA approvals, and analyst upgrades. A slight decline may indicate profit-taking or broader market influences.  

24-Hour: 1.3%
7-Day: 0.96%
30-Day: 10.51%

1-Year High: $14.80 on 2026-02-13  
1-Year Low: $7 on 2025-04-10  
  
  
### AltRank: [-----]
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:$amrx/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/$amrx/time-series/alt_rank.tsv)  
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is currently AltRank #1,539 based on combined combined social and market metrics
Daily Average: [-----]  
[--] Week: [-----] +992  
[--] Month: [-----] [---]  
[--] Months: [-----] [---]  
[--] Year: [-----] +341  
1-Year High: [-----] on 2026-02-04  
1-Year Low: [--] on 2025-08-23  
  
  
### Galaxy Score: [-----]
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:$amrx/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/$amrx/time-series/galaxy_score.tsv)  
Current Value: [-----]  
Daily Average: [--]  
[--] Week: [--] [---]  
[--] Month: [--] +14  
1-Year High: [--] on 2025-11-04  
1-Year Low: [--] on 2025-10-09  
  
  
### Engagements: [------] (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$amrx/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$amrx/time-series/interactions.tsv)  
Current Value: [------]  
Daily Average: [------]  
[--] Week: [-------] +217%  
[--] Month: [-------] -57%  
[--] Months: [---------] +245%  
[--] Year: [---------] +766%  
1-Year High: [-------] on 2025-08-20  
1-Year Low: [--] on 2026-01-03  

Engagements by network (24h):
X: [--]
YouTube: [------]
TikTok: [--]
Reddit: [--]

  
  
### Mentions: [--] (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$amrx/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$amrx/time-series/posts_active.tsv)  
Current Value: [--]  
Daily Average: [--]  
[--] Week: [--] -46%  
[--] Month: [---] +13%  
[--] Months: [---] -48%  
[--] Year: [-----] +119%  
1-Year High: [---] on 2025-06-28  
1-Year Low: [--] on 2025-10-26  

Mentions by network (24h):
X: [--]
YouTube: [--]
TikTok: [--]
Reddit: [--]

  
  
### Creators: [--] (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$amrx/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$amrx/time-series/contributors_active.tsv)  
[--] unique social accounts have posts mentioning Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) in the last [--] hours which is up 56% from [--] in the previous [--] hours
Daily Average: [--]  
[--] Week: [--] -49%  
[--] Month: [---] +14%  
[--] Months: [---] -64%  
[--] Year: [-----] +178%  
1-Year High: [---] on 2025-06-28  
1-Year Low: [--] on 2025-10-26  

The most influential creators that mention Amneal Pharmaceuticals, Inc. Class A Common Stock in the last [--] hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@linhnguyen64143](/creator/twitter/linhnguyen64143) | [--]    | [--]        | [--]     | [--]           |

[View More](/list/creators/$amrx/100)
  
  
### Sentiment: 100%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$amrx/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$amrx/time-series/sentiment.tsv)  
Current Value: 100%  
Daily Average: 88%  
[--] Week: 100% no change  
[--] Month: 100% +2%  
[--] Months: 100% no change  
[--] Year: 100% +17%  
1-Year High: 100% on 2025-02-20  
1-Year Low: 25% on 2025-03-16  

Most Supportive Themes:
- FDA Approvals: (40%) Amneal Pharmaceuticals has received several FDA approvals for its products, including epinephrine injection, albuterol sulfate inhalation aerosol, and iohexol injection. These approvals expand access to critical medicines and demonstrate the company's innovation.
- Analyst Upgrades: (20%) Analysts from firms like Piper Sandler and Barclays have upgraded Amneal Pharmaceuticals, with price targets indicating positive future outlooks. This suggests confidence from financial experts in the company's performance.
- Positive Phase [--] Results: (10%) Amneal Pharmaceuticals announced positive interim Phase [--] ELEVATE-PD results for CREXONT, a treatment for Parkinson's Disease. This indicates progress in clinical trials and potential for new therapeutic offerings.
  
Most Critical Themes:
- Margin Pressure: (30%) Despite strong revenue growth, Amneal Pharmaceuticals experienced only a 1% increase in adjusted EBITDA, indicating significant margin pressure. This suggests that while sales are increasing, profitability is not keeping pace.
- Patent Infringement Lawsuits: (25%) Amgen Inc. has filed patent infringement lawsuits against Amneal Pharmaceuticals and others over proposed biosimilar versions of its drugs. This legal challenge could impact the company's market share and revenue from these products.
  
  
  
### Social Dominance: 0.0009634647734797971%
![Social Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$amrx/c:line/m:social_dominance/iv:1d.svg)  
[Social Dominance 24-Hour Time-Series Raw Data](/topic/$amrx/time-series/social_dominance.tsv)  
Current Value: 0.0009634647734797971%  
Daily Average: 0.00447%  
[--] Week: 0.0025% +0.0018%  
[--] Month: 0.0011% -0.0012%  
[--] Months: 0.0011% -0.0023%  
[--] Year: 0.0011% -0.0041%  
1-Year High: 0.032% on 2025-06-29  
1-Year Low: 0.0003% on 2025-10-26  
  
  
### Market Dominance: 0.00528%
![Market Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$amrx/c:line/m:market_dominance/iv:1d.svg)  
[Market Dominance 24-Hour Time-Series Raw Data](/topic/$amrx/time-series/market_dominance.tsv)  
Current Value: 0.00528%  
Daily Average: 0%  
1-Year High: 0.211% on 2026-02-06  
1-Year Low: 0.00528% on 2026-02-14  
  
  
### Market Cap: $4,658,858,474
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:$amrx/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/$amrx/time-series/market_cap.tsv)  
Current Value: $4,658,858,474  
Daily Average: $3,620,944,619  
[--] Week: $4,658,858,474 +3.20%  
[--] Month: $4,658,858,474 +12%  
[--] Months: $4,658,858,474 +60%  
1-Year High: $4,658,858,474 on 2026-02-13  
1-Year Low: $2,908,374,401 on 2025-08-18  

### Top Amneal Pharmaceuticals, Inc. Class A Common Stock Social Posts
Top posts by engagements in the last [--] hours

*Showing a maximum of [--] top social posts without a LunarCrush subscription.*

"CREXONT (carbidopa and levodopa) extended-release capsules has transformed innovation into duration CREXONT Mechanism of Action (MOA) For patients and caregivers. For the rst time in Parkinsons disease an oral therapy was designed to target where levodopa is best absorbed the proximal small intestine-making CREXONT the oral CD/LD formulation with the longest-lasting LD plasma concentration  * ** References: *Exact site and duration of absorption are unknown. **Based on the time that LD plasma levels were above 50% of Cmax. [--]. Hauser RA Espay AJ Ellenbogen AL et al. IPX203 vs immediate-release"  
[YouTube Link](https://youtube.com/watch?v=mdENDnBb0R0) [@amnealpharma](/creator/youtube/amnealpharma) 2025-08-12T18:39Z [----] followers, 8.7M engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing